Events

Sign Up To Attend Free ODAC Virtual Workshops

By January 13, 2021No Comments

Dermatology Events

Events

Sign up now to attend Free ODAC Virtual 2021 Workshops

Sign up now to attend Free ODAC Virtual 2021 Workshops

The virtual ODAC conference, taking place January 14 – 17, 2021 is offering free workshops throughout the week.

Dermatologists do not need to be registered to attend ODAC to join the workshops, however, to attend, you must preregister for each session. View the workshop agenda below to save your spot.

To view the entire ODAC Conference agenda, click here.

  • In His Own Words: One Patient’s Journey with Dr. Alvaro Moreira

  • Wednesday, January 13th 7:00 PM ET
Sign Up Now
  • FDA Approved Label Expansion. Progress Your Topical Patients to the Next Step: An Oral Treatment With Data for Moderate to Severe Scalp Psoriasis with Lawrence Green, MD

  • Thursday, January 14th 7:15 PM ET
Sign Up Now
  •  ARAZLO™ Lotion: Tazarotene Redefined with Leon Kircik, MD

  • Friday, January 15th 12:00 PM ET
Sign Up Now
  • Behind the Brand – The DNA of La Roche-Posay with Adam Friedman, MD

  • Friday, January 15th 3:15 PM ET
Sign Up Now
  • Pathophysiology of Atopic Dermatitis with Marc Serota, MD, FAAD

  • Saturday, January 16th 12:00 PM ET
Sign Up Now

You May Also Like

JDD in the News: Topical Nonsteroidals for Chronic Hand Eczema

| Featured Articles, JDD in the Media, Latest News | No Comments
Physician’s Weekly interviewed dermatologist Geeta Yadav, MD, for her perspective on the March Journal of Drugs in Dermatology study, “Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.”…

Efficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study

| Aesthetics, Dyspigmentation, Featured Articles, Latest News | No Comments
Topical Metformin versus Kligman’s Formula for Melasma, a Split-Face JDD Study This is a must-read article from JDD a head-to-head split-face study asks whether topical metformin can be an effective,…

Longer Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study

| Featured Articles, Latest News, Oncodermatology, Skin Cancer | No Comments
Extended Pembrolizumab Duration Tied to Lower Mortality in Stage III and IV Melanoma: JDD Report Could extending pembrolizumab improve survival? This JDD is a must read. A new retrospective analysis…

Leave a Reply